Patients’ characteristics
| Discovery cohort | Validation cohort | ||||
| nSS /iSS (n=6/2) | pSS (n=8) | nSS (n=17) | iSS (n=16) | pSS (n=24) | |
| Female gender, n (%) | 8 (100) | 7 (88) | 15 (88) | 14 (88) | 21 (88) |
| Age, years (mean±SD) | 50±17 | 51±13 | 49±16 | 54±15 | 55±12 |
| Anti-Ro/SSA+, n (%) | 2 (25) | 6 (75) | 0 (0) | 10 (63) | 16 (67) |
| Anti-La/SSB+, n (%) | 0 (0) | 2 (25) | 0 (0) | 0 (0) | 4 (17) |
| ANA+, n (%) | 3 (38) | 6 (75) | 9 (53) | 7 (44) | 17 (71) |
| RF+, n (%) | 0 (0) | 3 (37.5) | 0 (0) | 1 (6) | 8 (33) |
| Lymphocytic focus score (foci/4 mm2) | 0 (0–0) | 1.8 (1.0–2.4) | 0 (0–0) | 0.2 (0–0.7) | 1.6 (1.0–2.6) |
| IgA+plasma cells (%) | 73(70–80) | 62 (45–67) | 77 (71–80) | 70 (68–76) | 59 (49–64) |
| Schirmer (mm/5 min) | 2 (0–11) | 7 (1–25) | 4 (1–7) | 10 (2–13) | 7 (3–11) |
| Serum IgG (g/L) | 10.8 (7.6–14.2) | 14.4 (11.8–19.0) | 11.0 (6.5–12.3) | 9.0 (8.0–13.6) | 13.9 (10.1–18.3) |
| ESR (mm/hour) | 7 (5–12) | 13 (7–50) | 7 (6–10) | 9 (5–15) | 15 (7–29) |
| ESSDAI score (0–123) | NA | 2 (0–6) | NA | NA | 3 (1–7) |
| ESSPRI score (0–10) | NA | 3.5 (1.6–5.4) | NA | NA | 5.3 (2.3–6.0) |
| Immunosuppressants, n (%) | 1 (12.5) | 1 (12.5) | 1 (6) | 2 (13) | 3 (12.5) |
Median with IQR are represented, unless specified otherwise.
ESR, erythrocyte sedimentation rate; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; RF, rheumatoid factor; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen B; iSS, incomplete Sjögren’s syndrome; nSS, non-Sjögren’s sicca; pSS, primary Sjögren’s syndrome.